Myocene Raises €3M to Accelerate International Commercialization
2024年6月18日 - 5:00PM
Myocene, the Liège-based sportstech company developing a unique,
cutting-edge device to objectively measure muscle fatigue, today
announced that it has raised a further €3m to accelerate its
growth, in particular the international commercialization of its
device on the European and American markets.
The innovative device developed by Myocene
computes the value of the muscle fatigue index in just two minutes.
The solution uses a dedicated algorithm to analyze accurate
measurements obtained using a specific sensor and very well
controlled muscle contractions. The device can be used both indoors
and outdoors, helping top-level athletes to manage their fatigue
and improve their performance. It also contributes to strength and
conditioning coaching by offering the possibility of adapting
training sessions and rest periods. It therefore helps preventing
the risks of overtraining and injury.
"Since the previous round in March 2023," says CEO
Jean-Yves Mignolet, "Myocene has signed contracts
with top European soccer clubs such as OGC Nice,
Sporting Club Braga and Paris-Saint Germain, among others. Over the
same period, more than eight hundred and fifty sportsmen
and women used it during their training sessions, and
more than ten thousand five hundred measurements
were taken, enabling fitness trainers to make
decisions on player training based on rationally
objective information. These measurements have also helped us
refine our device and improve user protocols, while confirming the
excellent reliability of the data collected."
The €3 million fund-raising that the Walloon company has
just completed with the participation of InvestSud,
Wallonie Entreprendre, Noshaq and the historical founders, partly
in capital and partly in a convertible loan, will be used to
accelerate the commercialization of the product on the European and
American markets.
"The Myocene device represents a profound change in the way
top-level athletes are monitored," adds Dr Pierre Rigaux,
Chairman and Founder. "The tests carried out since its
launch have enabled us to establish our technology as a benchmark
tool for measuring muscle fatigue in athletes. The three million
euros we've just raised will enable us to look forward with
confidence to growth in Europe and the launch of Myocene on the US
market in 2025, for which we have the highest hopes," he
concludes.
About Myocene
Myocene is a medical and sports technology company developing an
innovative device for measuring muscle fatigue. Fatigue is assessed
using patented algorithms to provide objective, precise,
quantifiable and rapid measurements. Using a combination of
electrostimulation and force sensors, Myocene's device measures a
fatigue index in just two minutes.
The application of the technology, already tested by almost
1,500 athletes, extends to the entire professional and
semi-professional sports market, filling an important gap in the
objective assessment of muscle fatigue, a fundamental parameter
linked to athletic performance. The Myocene device also offers
potential applications in the medical field (occupational medicine,
muscle pathologies).
Myocene's technology has been validated by Prof. Guillaume
Millet, a sports physiologist at the Jean Monnet University in
Saint-Etienne, France.
The company was founded in 2020 and is based in Liège,
Belgium.
Contact
Jean-Yves Mignolet, CEO
info@myocene.com